Mannkind Corporation
MNKDStock
$4.04+6.23%52W
Market Cap$1.26B
P/E214.99x
Div yield—
Beta1.11
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-39.54%
Price vs S&P 500 (4W)5.09%
VGM Score46.21
Market Capitalization$1.26B
P/E Ratio (Annual)214.99x
Earnings Surprise History
Q1 26-0.05est. -0.00
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.20
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
MNKDMannkind Corporation | D | C | B | $4.04 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
MannKind is a biopharmaceutical company commercializing therapies for cardiometabolic and orphan lung diseases. Its portfolio includes Afrezza, an ultra rapid-acting inhaled insulin for diabetes; Furoscix, a furosemide injection for heart failure and chronic kidney disease; and V-Go, a wearable device for continuous subcutaneous insulin infusion.